No Data
No Data
After the PD-1 era, the heavy-duty variety IND was accepted, and GSK (01167) is moving towards the fast lane.
According to the app Zhītōng Cáijīng, on July 10th, the National Medical Products Administration's Center for Drug Evaluation website showed that Jasco's (01167) broad-spectrum KRAS inhibitor, JAB-23E73 (previously named JAB-23400, JAB-23425), has had its New Drug Application (IND) for clinical trials accepted. This product is currently the global leader in oral broad-spectrum KRAS inhibitors. KRAS is a popular target pursued by domestic and foreign companies. There are 2.7 million new patients with KRAS mutations worldwide each year. As...
Jaccs-B (01167.HK) repurchased 163,500 shares for HKD 250,000 on June 27th.
Jiakesi-B (01167.HK) announced on June 27 that it spent HKD 250,000 to repurchase 163,500 shares.
On June 26, Jaks-B (01167.HK) spent HKD 223,000 to repurchase 139,500 shares.
On June 26th, JAKOS-B (01167.HK) announced the purchase of 139,500 shares for HKD 223,000.
Jiakesi-B (01167.HK) spent HKD 250,000 on June 25th to buy back 155,400 shares.
On June 25th, GKC-B (01167.HK) announced the repurchase of 155,400 shares for HKD 250,000.
On June 24th, Jaccs-B (01167.HK) spent HKD 256,000 to repurchase 160,500 shares.
On June 24th, Jaccs-B (01167.HK) announced that it spent HK$256,000 to repurchase 160,500 shares.
On June 21st, Jekoza-B (01167.HK) spent HKD 374,300 to repurchase 231,000 shares.
On June 21st, Geoscience-B (01167.HK) announced that it spent HKD 374,300 to repurchase 231,000 shares.
No Data